Additionally, the field of proteolysis lacks substantial evidence to support its ability to target and degrade tough and valuable undruggable proteins [14].Notably, despite the use of a poor inhibitor as an interactor, TUS-007 induced the chemical knockdown of both KRAS G12D and G12V in vivo, resulting in the suppression of a pancreatic tumor even in the orthotopic xenograft model involving oral administration (Figure 6). The gene discussed is KRAS; the disease is pancreatic neoplasm.